Zuzana Kratka

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/51446/publications.pdf

Version: 2024-02-01

		623574	677027
27	773	14	22
papers	citations	h-index	g-index

27	27	27	1080
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Drug-resistant hypertension in primary aldosteronism patients undergoing adrenal vein sampling: the AVIS-2-RH study. European Journal of Preventive Cardiology, 2022, 29, e85-e93.	0.8	19
2	Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. Hypertension, 2022, 79, 187-195.	1.3	13
3	Gene Profile of Adipose Tissue of Patients with Pheochromocytoma/Paraganglioma. Biomedicines, 2022, 10, 586.	1.4	3
4	Adherence and blood pressure control in patients with primary aldosteronism. Blood Pressure, 2022, 31, 58-63.	0.7	1
5	Adrenal Venous Sampling Could Be Omitted before Surgery in Patients with Connâ€™s Adenoma Confirmed by Computed Tomography and Higher Normal Aldosterone Concentration after Saline Infusion Test. Diagnostics, 2022, 12, 1718.	1.3	6
6	HIGH LEVEL OF PLASMA ALDOSTERONE AFTER SALINE INFUSION TEST IN COMBINATION WITH FINDING OF ADRENAL NODE ON CT SCAN CAN PREDICT ALDOSTERONE-PRODUCING ADENOMA MORE PRECISE THAN FINDING OF NODE ALONE. Journal of Hypertension, 2021, 39, e91.	0.3	0
7	EFFECT OF ADRENALECTOMY ON REMISSION OF SUBCLINICAL LEFT VENTRICULAR DYSFUNCTION IN PATIENTS WITH PHEOCHROMOCYTOMA: A SPECKLE-TRACKING ECHOCARDIOGRAPHY STUDY. Journal of Hypertension, 2021, 39, e225.	0.3	0
8	Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. Journal of Clinical Endocrinology and Metabolism, 2021, 106, e4340-e4349.	1.8	18
9	Blood Pressure Profile, Catecholamine Phenotype, and Target Organ Damage in Pheochromocytoma/Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5170-5180.	1.8	28
10	Catecholamines Induce Left Ventricular Subclinical Systolic Dysfunction: A Speckle-Tracking Echocardiography Study. Cancers, 2019, 11, 318.	1.7	13
11	FGF21 Levels in Pheochromocytoma/Functional Paraganglioma. Cancers, 2019, 11, 485.	1.7	2
12	(Prediction of long-term renal denervation efficacy). Cor Et Vasa, 2019, 61, e378-e384.	0.1	0
13	LONG-TERM EFFECT OF ADRENALECTOMY ON CARDIOVASCULAR REMODELING IN PATIENTS WITH PHEOCHROMOCYTOMA. Journal of Clinical Endocrinology and Metabolism, 2017, 102, jc.2016-2422.	1.8	14
14	Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension. Journal of Hypertension, 2017, 35, 1093-1099.	0.3	25
15	Combination antihypertensive therapy in clinical practice. The analysis of 1254 consecutive patients with uncontrolled hypertension. Journal of Human Hypertension, 2016, 30, 35-39.	1.0	19
16	Role of Adding Spironolactone and Renal Denervation in True Resistant Hypertension. Hypertension, 2016, 67, 397-403.	1.3	73
17	Long-term effect of specific treatment of primary aldosteronism on carotid intimaâ€“media thickness. Journal of Hypertension, 2015, 33, 874-882.	0.3	35
18	Long-term effects of adrenalectomy or spironolactone on blood pressure control and regression of left ventricle hypertrophy in patients with primary aldosteronism. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2015, 16, 1109-1117.	1.0	29

#	Article	IF	Citations
19	Biochemical Testing After Pheochromocytoma Removal: How Early?. Hormone and Metabolic Research, 2015, 47, e3-e3.	0.7	0
20	Biochemical Testing After Pheochromocytoma Removal: How Early?. Hormone and Metabolic Research, 2015, 47, 633-636.	0.7	1
21	Randomized Comparison of Renal Denervation Versus Intensified Pharmacotherapy Including Spironolactone in True-Resistant Hypertension. Hypertension, 2015, 65, 407-413.	1.3	178
22	Importance of thorough investigation of resistant hypertension before renal denervation: should compliance to treatment be evaluated systematically?. Journal of Human Hypertension, 2014, 28, 684-688.	1.0	23
23	Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. Journal of Hypertension, 2013, 31, 2455-2461.	0.3	136
24	Vascular Disturbances in Primary Aldosteronism: Clinical Evidence. Kidney and Blood Pressure Research, 2012, 35, 529-533.	0.9	30
25	Left ventricle remodeling in men with moderate to severe volume-dependent hypertension. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2012, 13, 426-434.	1.0	8
26	Pulse wave velocity in primary hyperparathyroidism and effect of surgical therapy. Hypertension Research, 2011, 34, 296-300.	1.5	42
27	The prevalence of metabolic syndrome and its components in two main types of primary aldosteronism. Journal of Human Hypertension, 2010, 24, 625-630.	1.0	57